Programmed death ligand-1 immunohistochemistry: Friend or foe?

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 4, 2016, Pages 326-331

  Kerr, Keith M ^a   Hirsch, Fred R ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

CARCINOMA, NON-SMALL-CELL LUNG; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LUNG NEOPLASMS; PATHOLOGY;

ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS;

EID: 84964031961     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2015-0522-SA     Document Type: Article

References (32)

1. Brahmer JR. Harnessing the immune system for the treatment of non-smallcell lung cancer. J Clin Oncol. 2013;31(8):1021-1028.
2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
3. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(suppl 8):viii6-viii8.
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
5. Schrieber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024): 1565-1570.
6. Yang CY, Lin MW, Chang YL, et al. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer. 2014; 50(7):1361-1369.
7. Wang A, Wang HY, Liu Y, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. 2015; 41(4):450-456.
8. Kerr KM, Tsao MS, Nicholson AG, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol. 2015;10(7):985-989.
9. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2): 123-135.
10. Spira AI, Park K, Mazières J, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR) [abstract]. J Clin Oncol. 2015;33(15)(suppl):8010.
11. Dolled-Filhart M, Roach CM, Toland G, et al. Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2015;33(15)(suppl):11065.
12. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.
13. Dako. PD-L1 IHC 28-8 pharmDx for Autostainer Link 48. http://www. dako.com/us/ar39/p251310/prod-products.htm. Accessed December 11, 2015.
14. Phillips T, Simmons P, Inzunza HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015;23(8):541-549
15. Dako. PD-L1 IHC 22C3 pharmDx for Autostainer Link 48. http://www. dako.com/us/ar39/p250165/prod-products.htm. Accessed December 11, 2015.
16. US Food and Drug Administration. Public workshop-complexities in personalized medicine: harmonizing companion diagnostics across a class of targeted therapies, March 24, 2015. http://www.fda.gov/MedicalDevices/ NewsEvents/WorkshopsConferences/ucm436716.htm. Accessed December 11, 2015.
17. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2013;94(1):107-116.
18. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2(1):46-54.
19. Milne CP, Bryan C, Garafalo S, et al. Complementary versus companion diagnostics: apples and oranges? Biomark Med. 2015;9(1):25-34.
20. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med. 2013;137(5):668-684.
21. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-128.
22. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17): 1627-1639.
23. Howitt BE, Sholl LM, Ritterhouse L, et al. Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1 [abstract]. J Clin Oncol. 2015;33(15)(suppl):5511.
24. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency [abstract]. J Clin Oncol. 2015;33(18)(suppl):LBA100.
25. Ulloa-Montoya F, Louahed J, Dizier B, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol. 2013;31(19): 2388-2395.
26. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the "Immunoscore" in the classification of malignant tumours. J Pathol. 2014;232(2): 199-209.
27. Gettinger SN, Kowanetz M, Koeppen H, et al. Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A [abstract]. J Clin Oncol. 2015;33(15)(suppl):3015.
28. Yearley J, Gibson C, Yu N, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Eur J Cancer. 2015;51(suppl 3);S718, 18LBA.
29. Higgs BW, Robbins PB, Blake-Haskins JA, et al. High tumoral IFNg mRNA, PD-L1 protein, and combined IFNg mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients. Eur J Cancer. 2015;51(suppl 3);S717, 15LBA.
30. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-265.
31. Rizvi NA, Brahmer JR, Ou S-HI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2015; 33(15)(suppl):8032.
32. Gulley LJ, Spigel D, Kelly K, et al. Avelumab (MSB0010718C), an anti-PDL1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy [abstract]. J Clin Oncol. 2015;33(15)(suppl):8034.